搜尋結果
special reports. In an interview with MIMS Doctor, Dr Ka-Yuen Lock, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, discussed management of diabetes mellitus (DM), including use of ultra-long-acting insulin, in optimizing glycaemic control. She also shared a case study illustrating improvements in glucose variability and ...
IM Primary vaccination schedule of 2 doses (0.5 mL each): Initial dose followed by 2nd dose 2 mth later. If flexibility in the vaccination schedule is necessary, 2nd dose can be administered between 2 & 6 mth after the 1st dose. Immunodeficient or immunosuppressed individual 2nd dose can be given 1-2 mth after the initial dose.
Per 0.5 mL Diphtheria toxoid ≥30 IU, tetanus toxoid ≥40 IU, Bordetella pertussis antigens: Pertussis toxoid 25 mcg, filamentous haemagglutinin 25 mcg, inactivated poliomyelitis virus (type 1) 40 D antigen units, inactivated poliomyelitis virus (type 2) 8 D antigen units, inactivated poliomyelitis virus (type 3) 32 D antigen units, H. influenzae type b polysaccharide 10 mcg, conjugated to ...
Dosage/Direction for Use. IM 2 inj at 2-mth intervals (1 at the age of 2 mth & 1 at the age of 4 mth), followed by 1 booster inj at the age of 11 mth, then another booster inj at the age of 6 yr; booster vaccination for childn 11-13 yr who did not receive a vaccine containing the pertussis valence at normal conc at the age of 6 yr ...
Dosage/Direction for Use. 10 mg once daily. Patient w/ severe hepatic impairment Initially 5 mg, may be increased to 10 mg if well tolerated. Click to view Forxiga detailed prescribing information.
2021年3月9日 · Haematologists from the University of Hong Kong (HKU) have reported initial success with chimeric antigen receptor (CAR) T-cell therapy, treating the first patient in Hong Kong in May 2020 in a global lymphoma trial and another leukaemia patient in October 2020 in
Tagrisso FC tab 40 mg. Packing/Price. 30's. Form. Tagrisso FC tab 80 mg. Packing/Price. 30's. Tagrisso (Osimertinib mesylate): Adjuvant treatment after complete tumour resection in adults w/ stage IB-IIIA NSCLC whose tumours have epidermal growth fac.
